BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/27/2022 11:37:03 AM | Browse: 349 | Download: 931
 |
Received |
|
2021-10-27 11:20 |
|
Peer-Review Started |
|
2021-10-27 11:23 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-12-27 01:39 |
|
Revised |
|
2021-12-31 05:40 |
|
Second Decision |
|
2022-04-15 02:03 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-04-15 20:19 |
|
Articles in Press |
|
2022-04-15 20:19 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-05-19 01:41 |
|
Publish the Manuscript Online |
|
2022-05-27 11:37 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Advances in medical treatment for pancreatic neuroendocrine neoplasms
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yuan-Liang Li, Zi-Xuan Cheng, Fu-Huan Yu, Chao Tian and Huang-Ying Tan |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Key R&D Program of China |
2019YFB1309704 |
|
| Corresponding Author |
Huang-Ying Tan, MD, PhD, Professor, Department of Integrative Oncology, China-Japan Friendship Hospital, No. 2 Yinghuayuan East Street, Chaoyang District, Beijing 100029, China. tanhuangying@263.net |
| Key Words |
Pancreatic neuroendocrine neoplasms; Advanced neuroendocrine tumors; Medical treatment; Peptide receptor radionuclide therapy; Advances |
| Core Tip |
Pancreatic neuroendocrine neoplasms (PanNENs) are rare neoplasms with strong heterogeneity. The systemic treatment options of advanced PanNENs vary due to the different differentiations, grades and stages and include somatostatin analogs, molecularly targeted agents, cytotoxic chemotherapeutic agents, immune checkpoint inhibitors, and peptide receptor radionuclide therapy. Despite the multiple systemic therapeutic options for PanNENs, problems such as drug resistance, adverse side effects and limited scope of application still exist. Thus, we review the clinical development of medical treatment options, focusing on ongoing clinical studies and the development of novel targeted drugs, to provide a reference for clinicians and researchers. |
| Publish Date |
2022-05-27 11:37 |
| Citation |
Li YL, Cheng ZX, Yu FH, Tian C, Tan HY. Advances in medical treatment for pancreatic neuroendocrine neoplasms. World J Gastroenterol 2022; 28(20): 2163-2175 |
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i20/2163.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i20.2163 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
